152 related articles for article (PubMed ID: 23761968)
1. Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis.
Chung HY; Koo J; Kwon SK; Kang MI; Moon SH; Park JY; Shin CS; Yoon BK; Yoon HK; Chang JS; Chung YS; Park HM
Clin Interv Aging; 2013; 8():597-603. PubMed ID: 23761968
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis.
Chung HY; Chin SO; Kang MI; Koh JM; Moon SH; Yoon BK; Yoon HK; Chung YS; Park HM
Clin Endocrinol (Oxf); 2011 Jun; 74(6):699-704. PubMed ID: 21521310
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis.
Park SY; Kang MI; Park HM; Rhee Y; Moon SH; Yoon HK; Koh JM; Chang JS; Kim IJ; Won YY; Park YS; Choi H; Shin CS; Yoon TR; Yun SC; Chung HY;
Arch Osteoporos; 2019 Dec; 15(1):3. PubMed ID: 31820121
[TBL] [Abstract][Full Text] [Related]
4. The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.
Dundar U; Kavuncu V; Ciftci IH; Evcik D; Solak O; Cakir T
J Bone Miner Metab; 2009; 27(4):464-70. PubMed ID: 19301089
[TBL] [Abstract][Full Text] [Related]
5. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
Recker R; Lips P; Felsenberg D; Lippuner K; Benhamou L; Hawkins F; Delmas PD; Rosen C; Emkey R; Salzmann G; He W; Santora AC
Curr Med Res Opin; 2006 Sep; 22(9):1745-55. PubMed ID: 16968578
[TBL] [Abstract][Full Text] [Related]
6. Between-meal risedronate does not alter bone turnover in nursing home residents.
Agrawal S; Krueger DC; Engelke JA; Nest LJ; Krause PF; Drinka PJ; Binkley NC
J Am Geriatr Soc; 2006 May; 54(5):790-5. PubMed ID: 16696745
[TBL] [Abstract][Full Text] [Related]
7. Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
Chung YS; Lim SK; Chung HY; Lee IK; Park IH; Kim GS; Min YK; Kang MI; Chung DJ; Kim YK; Choi WH; Shong MH; Park JH; Byun DW; Yoon HK; Shin CS; Lee YS; Kwon NH
Calcif Tissue Int; 2009 Nov; 85(5):389-97. PubMed ID: 19816648
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
Ste-Marie LG; Brown JP; Beary JF; Matzkin E; Darbie LM; Burgio DE; Racewicz AJ
Clin Ther; 2009 Feb; 31(2):272-85. PubMed ID: 19302900
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a Once-Monthly Pill Containing Ibandronate and Cholecalciferol on the Levels of 25-Hydroxyvitamin D and Bone Markers in Postmenopausal Women with Osteoporosis.
Cho IJ; Chung HY; Kim SW; Lee JW; Lee TW; Kim HS; Kim SG; Choi HS; Choi SH; Shin CS; Oh KW; Min YK; Koh JM; Rhee Y; Byun DW; Chung YS; Park JH; Chung DJ; Shong M; Hong EG; Lee CB; Baek KH; Kang MI
Endocrinol Metab (Seoul); 2015 Sep; 30(3):272-9. PubMed ID: 25491782
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S; Delmas P
Osteoporos Int; 2013 Jan; 24(1):293-9. PubMed ID: 22752050
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis.
Li Y; Zhang Z; Deng X; Chen L
J Huazhong Univ Sci Technolog Med Sci; 2005; 25(5):527-9. PubMed ID: 16463664
[TBL] [Abstract][Full Text] [Related]
12. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
13. Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study.
Racewicz AJ; Schofield PJ; Cahall DL; Cline GA; Burgio DE
Curr Med Res Opin; 2007 Dec; 23(12):3079-89. PubMed ID: 17971285
[TBL] [Abstract][Full Text] [Related]
14. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).
Shiraki M; Fukunaga M; Kushida K; Kishimoto H; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H
Osteoporos Int; 2003 May; 14(3):225-34. PubMed ID: 12730746
[TBL] [Abstract][Full Text] [Related]
15. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
Bahlous A; Bouzid K; Sahli H; Sallami S; Abdelmoula J
Tunis Med; 2009 Jun; 87(6):380-1. PubMed ID: 19927782
[TBL] [Abstract][Full Text] [Related]
16. Effects of alendronate and calcifediol compared to alendronate and cholecalciferol in osteoporotic patients.
Giampà E; Di Bonito M; Ferretti V; Nuvoli G; Paoletti F; Piazzini M; Ranieri M; Tuveri MA; Vinicola V
Minerva Endocrinol; 2019 Dec; 44(4):344-350. PubMed ID: 31971357
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Vitamin D Insufficiency in Postmenopausal Women: A Randomized Clinical Trial.
Hansen KE; Johnson RE; Chambers KR; Johnson MG; Lemon CC; Vo TN; Marvdashti S
JAMA Intern Med; 2015 Oct; 175(10):1612-21. PubMed ID: 26237520
[TBL] [Abstract][Full Text] [Related]
18. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
[TBL] [Abstract][Full Text] [Related]
19. The effect of cholecalciferol and calcitriol on biochemical bone markers in HIV type 1-infected males: results of a clinical trial.
Bang UC; Kolte L; Hitz M; Schierbeck LL; Nielsen SD; Benfield T; Jensen JE
AIDS Res Hum Retroviruses; 2013 Apr; 29(4):658-64. PubMed ID: 23199009
[TBL] [Abstract][Full Text] [Related]
20. Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study.
Chandra P; Binongo JN; Ziegler TR; Schlanger LE; Wang W; Someren JT; Tangpricha V
Endocr Pract; 2008; 14(1):10-7. PubMed ID: 18238736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
